The nation of Zimbabwe has turned down a significant US health deal valued at 367 million US dollars (£272m) spanning five years over Washington's demand for confidential biological samples.
The decision came to light after a internal memorandum from December was leaked, indicating that Head of State Emmerson Mnangagwa believed the arrangement was "lopsided".
An official spokesperson later clarified that the United States was seeking health data for research and profit but refused to share the resulting advantages from any future vaccines.
"We are forced to start the difficult and regrettable task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for continued talks to find a deal acceptable to both sides so the nation's vital HIV programme can proceed.
Wider Background
This rejection comes after a comparable situation in Kenya, where a high court blocked a similar health funding agreement following legal challenges were filed about the safety of citizens' medical information.
After resuming the presidency recently, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing government-to-government deals to enhance transparency and accountability.
Based on statements, 16 African countries have so far signed similar agreements, constituting over $18.3bn in new funding.
Specifics of the Declined Agreement
The funds for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on antiretroviral therapy via American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, with no equivalent assurance of access to any medical innovations – like new medicines or tests – that might be developed from that shared data," his statement read.
"Put simply, our country would provide the basic resources for scientific discovery with no assurance that the final treatments would be accessible to our population should a future health crisis arise."
National Interest and Global Health
He also said that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were disrupting frameworks already set up via the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to manage future global health emergencies.
"This mechanism is designed to guarantee that when a country provides its data, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to develop them."
These objections regarding the US deal "must not be interpreted as opposition to America," he added.
"We welcome further dialogue with our American counterparts on how subsequent collaboration could be designed in a manner that honours the independence and interests of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but recommended that talks should continue given that a large portion of the country's Aids initiatives relied on external financing.
"Where technical issues arise, such as those involving data governance or agreement terms, these can frequently be addressed through technical clarification and negotiated safeguards," it commented.
The halted deal underscores the complex challenges between receiving vital foreign assistance and protecting national sovereignty in an increasingly data-driven world.